Literature DB >> 30089426

Projected Contributions of Nurse Practitioners and Physicians Assistant to Buprenorphine Treatment Services for Opioid Use Disorder in Rural Areas.

C Holly A Andrilla1, Davis G Patterson1, Tessa E Moore1, Cynthia Coulthard1, Eric H Larson1.   

Abstract

The United States is experiencing an opioid use disorder epidemic. The Comprehensive Addiction and Recovery Act allows nurse practitioners (NPs) and physician assistants (PAs) to obtain a Drug Enforcement Administration waiver to prescribe medication-assisted treatment (MAT) for opioid use disorder. This study projected the potential increase in MAT availability provided by NPs and PAs for rural patients. Using workforce and survey data, and state scope of practice regulations, the number of treatment slots that could be provided by NPs and PAs was estimated for rural areas. NPs and PAs are projected to increase the number of rural patients treated with buprenorphine by 10,777 (15.2%). Census Divisions varied substantially in the number of projected new treatment slots per 10,000 population (0.8-10.6). The New England and East South Central Census Divisions are projected to have the largest population-adjusted increase. NPs and PAs have considerable potential to reduce substantial MAT access disparities.

Entities:  

Keywords:  CARA 2016; buprenorphine; medication-assisted treatment; opioid treatment; opioid use disorder; rural health

Mesh:

Substances:

Year:  2018        PMID: 30089426     DOI: 10.1177/1077558718793070

Source DB:  PubMed          Journal:  Med Care Res Rev        ISSN: 1077-5587            Impact factor:   3.929


  9 in total

1.  Naloxone perspectives from people who use opioids: Findings from an ethnographic study in three states.

Authors:  Miriam Boeri; Aukje K Lamonica
Journal:  J Am Assoc Nurse Pract       Date:  2020-04-01       Impact factor: 1.165

2.  Assessing the needs of front-line providers in addressing the opioid crisis in South Carolina.

Authors:  Angela Moreland; Jenna McCauley; Kelly Barth; Carolyn Bogdon; Therese Killeen; Louise Haynes; Lindsey Jennings; Constance Guille; Sara Goldsby; Kathleen Brady
Journal:  J Subst Abuse Treat       Date:  2019-06-13

3.  Demystifying buprenorphine misuse: Has fear of diversion gotten in the way of addressing the opioid crisis?

Authors:  Molly Doernberg; Noa Krawczyk; Deborah Agus; Michael Fingerhood
Journal:  Subst Abus       Date:  2019-04-22       Impact factor: 3.716

4.  In Rural Areas, Buprenorphine Waiver Adoption Since 2017 Driven By Nurse Practitioners And Physician Assistants.

Authors:  Michael L Barnett; Dennis Lee; Richard G Frank
Journal:  Health Aff (Millwood)       Date:  2019-12       Impact factor: 6.301

5.  Buprenorphine waiver uptake among nurse practitioners and physician assistants: The role of existing waivered prescriber supply.

Authors:  Samantha G Auty; Michael D Stein; Alexander Y Walley; Mari-Lynn Drainoni
Journal:  J Subst Abuse Treat       Date:  2020-05-13

6.  Beyond state scope of practice laws for advanced practitioners: Additional supervision requirements for buprenorphine prescribing.

Authors:  Barbara Andraka-Christou; Adam J Gordon; Joanne Spetz; Rachel Totaram; Matthew Golan; Olivia Randall-Kosich; Jordan Harrison; Spencer Calder; Stefan G Kertesz; Bradley D Stein
Journal:  J Subst Abuse Treat       Date:  2022-01-10

Review 7.  Implications of Increased Access to Buprenorphine for Medical Providers in Rural Areas: A Review of the Literature and Future Directions.

Authors:  Hannah M Gregory; Veronica M Hill; Robert W Parker
Journal:  Cureus       Date:  2021-11-24

8.  Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants.

Authors:  Barbara Andraka-Christou; Cory Page; Victoria Schoebel; Jessica Buche; Rebecca L Haffajee
Journal:  Addict Sci Clin Pract       Date:  2022-08-09

9.  The Association Between Scope of Practice Regulations and Nurse Practitioner Prescribing of Buprenorphine After the 2016 Opioid Bill.

Authors:  Thuy Nguyen; Ulrike Muench; Barbara Andraka-Christou; Kosali Simon; W David Bradford; Joanne Spetz
Journal:  Med Care Res Rev       Date:  2021-04-01       Impact factor: 3.929

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.